Leprosy and HIV: an analysis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2000 |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Hansenologia Internationalis (Online) |
Texto Completo: | https://periodicos.saude.sp.gov.br/hansenologia/article/view/35379 |
Resumo: | After the introduction of HIV in the community, the number of patients with tuberculosis increased. Many of the HIV iníected patients suffer from clinical tuberculosis. Other mycobacterial infections too have an increased incidence among the HIV infected patients, but not so leprosy. Many researchers have looked into this observation, however with conflicting results. But a major increase in leprosy prevalence among HIV infected patients was never encountered, nor a significant increase oí HIV seroprevalence among leprosy patients. In Africa during the past 30 years a continuous fall in the leprosy incidence was seen. However in recent years the decline seems to come to a halt and in some areas an increase is observed. The author speculates that M.leprae does not cause clinical disease in already HIV infected patients, since M.leprae is virtually non-toxic and needs a more or less functioning CMI to cause clinical disease. However the bacterium will multiply, the patient becoming a multibacillary carrier contributing to the infective mycobacterial pool. The non-HIV infected persons then have more chance to be infected and may develop clinical leprosy since they have a functioning CMI. The author thereíore forecast an increase in leprosy incidence over the coming decade in countries, like Brazil, with endemic leprosy, where at present HIV íinds a foothold. |
id |
ILSL-1_539b9cce3cda7e86136748494e368c51 |
---|---|
oai_identifier_str |
oai:ojs.periodicos.saude.sp.gov.br:article/35379 |
network_acronym_str |
ILSL-1 |
network_name_str |
Hansenologia Internationalis (Online) |
repository_id_str |
|
spelling |
Leprosy and HIV: an analysisHanseníase e HIV: uma análiseHanseníaseHIVEpidemiologiaLeprosyHIVEpidemiologAfter the introduction of HIV in the community, the number of patients with tuberculosis increased. Many of the HIV iníected patients suffer from clinical tuberculosis. Other mycobacterial infections too have an increased incidence among the HIV infected patients, but not so leprosy. Many researchers have looked into this observation, however with conflicting results. But a major increase in leprosy prevalence among HIV infected patients was never encountered, nor a significant increase oí HIV seroprevalence among leprosy patients. In Africa during the past 30 years a continuous fall in the leprosy incidence was seen. However in recent years the decline seems to come to a halt and in some areas an increase is observed. The author speculates that M.leprae does not cause clinical disease in already HIV infected patients, since M.leprae is virtually non-toxic and needs a more or less functioning CMI to cause clinical disease. However the bacterium will multiply, the patient becoming a multibacillary carrier contributing to the infective mycobacterial pool. The non-HIV infected persons then have more chance to be infected and may develop clinical leprosy since they have a functioning CMI. The author thereíore forecast an increase in leprosy incidence over the coming decade in countries, like Brazil, with endemic leprosy, where at present HIV íinds a foothold.Após a introdução do HIV, o número de pacientes com tuberculose aumentou e muitos deles, infectados com o HIV, sofrem de tuberculose. Em outras infecções micobacterianas, também foi demonstrada uma incidência aumentada nos pacientes infectados com o HIV, mas não na hanseníase. Muitos pesquisadores têm observado isso, mas os resultados têm sido conflitantes. Nos pacientes com HIV, contudo, nunca foi encontrado um aumento maior na prevalência da hanseníase e nem um aumento significativo de soroprevalência para o HIV entre os pacientes com hanseníase. Na África, durante os últimos 30 anos, tem sido vista uma contínua queda na incidência da hanseníase. Contudo, em anos recentes, esse declínio parece ter feito uma parada e, em algumas áreas, foi observado até um aumento dessa incidência. O autor considera que o Mycobacterium leprae não causa a doença em pacientes já infectados com o HIV, posto que o Mycobacterium leprae é virtualmente não tóxico e necessita uma imunidade mediada por células (CMI) mais ou menos funcionante para causar a doença clínica. Contudo, a bactéria se multiplicará, tornando o paciente um portador multibacilar, contribuindo para o "pool" infeccioso micobacteriano. Pessoas não infectadas com o HIV, então, têm mais chance de poderem desenvolver a hanseníase, visto que elas têm um CMIfuncionante. Por isso, o autor prevê um aumento da incidência da hanseníase na próxima década em países endêmicos como o Brasil, onde, no presente, o HIV encontra asilo.Instituto Lauro de Souza Lima da Secretaria de Estado da Saúde de São Paulo2000-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionNão avaliado pelos paresapplication/pdfapplication/pdfhttps://periodicos.saude.sp.gov.br/hansenologia/article/view/3537910.47878/hi.2000.v25.35379Hansenologia Internationalis: leprosy and other infectious diseases; Vol. 25 No. 1 (2000); 60-62Hansenologia Internationalis: hanseníase e outras doenças infecciosas; v. 25 n. 1 (2000); 60-621982-5161reponame:Hansenologia Internationalis (Online)instname:Instituto Lauro de Souza Lima (ILSL)instacron:ILSLporenghttps://periodicos.saude.sp.gov.br/hansenologia/article/view/35379/33812https://periodicos.saude.sp.gov.br/hansenologia/article/view/35379/33813Naafs, Beninfo:eu-repo/semantics/openAccess2021-05-19T21:11:31Zoai:ojs.periodicos.saude.sp.gov.br:article/35379Revistahttps://periodicos.saude.sp.gov.br/hansenologiaPRIhttps://periodicos.saude.sp.gov.br/hansenologia/oaihansen_int@ilsl.br || hansenologia.internationalis@gmail.com || periodicossp@saude.sp.gov.br1982-51610100-3283opendoar:2021-05-19T21:11:31Hansenologia Internationalis (Online) - Instituto Lauro de Souza Lima (ILSL)false |
dc.title.none.fl_str_mv |
Leprosy and HIV: an analysis Hanseníase e HIV: uma análise |
title |
Leprosy and HIV: an analysis |
spellingShingle |
Leprosy and HIV: an analysis Naafs, Ben Hanseníase HIV Epidemiologia Leprosy HIV Epidemiolog |
title_short |
Leprosy and HIV: an analysis |
title_full |
Leprosy and HIV: an analysis |
title_fullStr |
Leprosy and HIV: an analysis |
title_full_unstemmed |
Leprosy and HIV: an analysis |
title_sort |
Leprosy and HIV: an analysis |
author |
Naafs, Ben |
author_facet |
Naafs, Ben |
author_role |
author |
dc.contributor.author.fl_str_mv |
Naafs, Ben |
dc.subject.por.fl_str_mv |
Hanseníase HIV Epidemiologia Leprosy HIV Epidemiolog |
topic |
Hanseníase HIV Epidemiologia Leprosy HIV Epidemiolog |
description |
After the introduction of HIV in the community, the number of patients with tuberculosis increased. Many of the HIV iníected patients suffer from clinical tuberculosis. Other mycobacterial infections too have an increased incidence among the HIV infected patients, but not so leprosy. Many researchers have looked into this observation, however with conflicting results. But a major increase in leprosy prevalence among HIV infected patients was never encountered, nor a significant increase oí HIV seroprevalence among leprosy patients. In Africa during the past 30 years a continuous fall in the leprosy incidence was seen. However in recent years the decline seems to come to a halt and in some areas an increase is observed. The author speculates that M.leprae does not cause clinical disease in already HIV infected patients, since M.leprae is virtually non-toxic and needs a more or less functioning CMI to cause clinical disease. However the bacterium will multiply, the patient becoming a multibacillary carrier contributing to the infective mycobacterial pool. The non-HIV infected persons then have more chance to be infected and may develop clinical leprosy since they have a functioning CMI. The author thereíore forecast an increase in leprosy incidence over the coming decade in countries, like Brazil, with endemic leprosy, where at present HIV íinds a foothold. |
publishDate |
2000 |
dc.date.none.fl_str_mv |
2000-06-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Não avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://periodicos.saude.sp.gov.br/hansenologia/article/view/35379 10.47878/hi.2000.v25.35379 |
url |
https://periodicos.saude.sp.gov.br/hansenologia/article/view/35379 |
identifier_str_mv |
10.47878/hi.2000.v25.35379 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://periodicos.saude.sp.gov.br/hansenologia/article/view/35379/33812 https://periodicos.saude.sp.gov.br/hansenologia/article/view/35379/33813 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Instituto Lauro de Souza Lima da Secretaria de Estado da Saúde de São Paulo |
publisher.none.fl_str_mv |
Instituto Lauro de Souza Lima da Secretaria de Estado da Saúde de São Paulo |
dc.source.none.fl_str_mv |
Hansenologia Internationalis: leprosy and other infectious diseases; Vol. 25 No. 1 (2000); 60-62 Hansenologia Internationalis: hanseníase e outras doenças infecciosas; v. 25 n. 1 (2000); 60-62 1982-5161 reponame:Hansenologia Internationalis (Online) instname:Instituto Lauro de Souza Lima (ILSL) instacron:ILSL |
instname_str |
Instituto Lauro de Souza Lima (ILSL) |
instacron_str |
ILSL |
institution |
ILSL |
reponame_str |
Hansenologia Internationalis (Online) |
collection |
Hansenologia Internationalis (Online) |
repository.name.fl_str_mv |
Hansenologia Internationalis (Online) - Instituto Lauro de Souza Lima (ILSL) |
repository.mail.fl_str_mv |
hansen_int@ilsl.br || hansenologia.internationalis@gmail.com || periodicossp@saude.sp.gov.br |
_version_ |
1796797579316428800 |